These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17435427)

  • 1. Pharmacoeconomics and macular degeneration.
    Brown GC; Brown MM; Brown H; Godshalk AN
    Curr Opin Ophthalmol; 2007 May; 18(3):206-11. PubMed ID: 17435427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to interpret a healthcare economic analysis.
    Brown MM; Brown GC
    Curr Opin Ophthalmol; 2005 Jun; 16(3):191-4. PubMed ID: 15870578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on utilities and cost-utility analyses.
    Hollands H; Sharma S
    Curr Opin Ophthalmol; 2006 Jun; 17(3):223-7. PubMed ID: 16794433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration.
    Brown MM; Brown GC; Brown HC; Peet J
    Ophthalmology; 2008 Jun; 115(6):1039-1045.e5. PubMed ID: 17976724
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparative effectiveness and cost-effectiveness of vitreoretinal interventions.
    Brown MM; Brown GC; Brown HC; Irwin B; Brown KS
    Curr Opin Ophthalmol; 2008 May; 19(3):202-7. PubMed ID: 18408494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age-related macular degeneration: the costs to society and the patient.
    Gupta OP; Brown GC; Brown MM
    Curr Opin Ophthalmol; 2007 May; 18(3):201-5. PubMed ID: 17435426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of vision for vitreoretinal interventions.
    Smiddy WE
    Curr Opin Ophthalmol; 2008 May; 19(3):195-201. PubMed ID: 18408493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of age-related macular degeneration: a value-based analysis.
    Brown MM; Brown GC; Sharma S; Stein JD; Roth Z; Campanella J; Beauchamp GR
    Curr Opin Ophthalmol; 2006 Jun; 17(3):257-66. PubMed ID: 16794438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomics.
    Sule NS; Nerurkar RP; Kamath SA
    J Assoc Physicians India; 2002 Aug; 50():1057-62. PubMed ID: 12421032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomics.
    Ahuja J; Gupta M; Gupta AK; Kohli K
    Natl Med J India; 2004; 17(2):80-3. PubMed ID: 15141600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value-Based Medicine and Pharmacoeconomics.
    Brown GC; Brown MM
    Dev Ophthalmol; 2016; 55():381-90. PubMed ID: 26501688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computerized model of cost-utility analysis for treatment of age-related macular degeneration.
    Fletcher EC; Lade RJ; Adewoyin T; Chong NV
    Ophthalmology; 2008 Dec; 115(12):2192-8. PubMed ID: 18930556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration].
    Neubauer AS; Holz FG; Schrader W; Back EI; Kühn T; Hirneiss C; Kampik A
    Klin Monbl Augenheilkd; 2007 Sep; 224(9):727-32. PubMed ID: 17846963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value-based medicine and interventions for macular degeneration.
    Brown MM; Brown GC; Brown H
    Curr Opin Ophthalmol; 2007 May; 18(3):194-200. PubMed ID: 17435425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of treatment of age-related macular degeneration: a review.
    Kymes Steven M
    Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacoeconomics of hypertension control: basic principles of economic evaluation.
    Wilson TW; Chockalingam A; Quest DW
    J Hum Hypertens; 1996 Feb; 10 Suppl 2():S19-22. PubMed ID: 8868039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomics--an aid to better decision-making.
    Arenas-Guzman R; Tosti A; Hay R; Haneke E;
    J Eur Acad Dermatol Venereol; 2005 Sep; 19 Suppl 1():34-9. PubMed ID: 16120204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
    Weintraub WS
    J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacoeconomics of asthma].
    Jahnz-Rózyk K; Targowski T
    Pol Merkur Lekarski; 2004 May; 16 Suppl 1():48-9. PubMed ID: 15524016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.